Hepatitis C infection among men who have sex with men living with HIV in New York City, 2000–2015

2019 ◽  
Vol 96 (6) ◽  
pp. 445-450
Author(s):  
Claudia Michelle Gabai ◽  
Miranda S Moore ◽  
Katherine Penrose ◽  
Sarah Braunstein ◽  
Angelica Bocour ◽  
...  

ObjectivesTo calculate the rate of hepatitis C virus (HCV) among HIV-infected men who have sex with men (MSM) with no reported history of injection drug use (IDU), and to assess whether disparities exist in HIV/HCV coinfection by race/ethnicity and neighbourhood poverty level within this population in New York City.MethodsHIV-positive men who reported sex with men and did not report IDU at the time of HIV diagnosis, diagnosed through 2015 and alive as of 2000, were matched to people with HCV first reported to the New York City Department of Health and Mental Hygiene between 2000 and 2015. Those with HCV reported before or within 90 days of HIV infection were excluded. A multivariable Cox proportional hazards model was fit to compare the association between HCV diagnosis, race/ethnicity and neighbourhood poverty level.ResultsFrom 2000 to 2015, 54 488 non-IDU MSM were diagnosed with HIV, of whom 2762 (5.1%) were diagnosed with HCV after HIV diagnosis, yielding an overall age-adjusted HCV diagnosis rate of 512 per 100 000 person-years. HIV/HCV coinfection was significantly higher among non-Latino blacks (adjusted HR (aHR)=1.24, 95% CI 1.11 to 1.40) compared with non-Latino whites and among persons living in high-poverty neighbourhoods compared with those in low-poverty neighbourhoods (aHR=1.17, 95% CI 1.01 to 1.35) after stratification by year of HIV diagnosis.ConclusionDisparities in HIV/HCV coinfection among HIV-positive MSM were observed by race/ethnicity and neighbourhood poverty level. Routine HCV screening is recommended for people infected with HIV. People coinfected with HIV and HCV should be linked to HCV care, treated and cured to reduce morbidity and mortality, and to avoid ongoing HCV transmission.

PLoS ONE ◽  
2018 ◽  
Vol 13 (7) ◽  
pp. e0200269 ◽  
Author(s):  
Hong-Van Tieu ◽  
Oliver Laeyendecker ◽  
Vijay Nandi ◽  
Rebecca Rose ◽  
Reinaldo Fernandez ◽  
...  

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Ofole Mgbako ◽  
Ellen Benoit ◽  
Nishanth S. Iyengar ◽  
Christopher Kuhner ◽  
Dustin Brinker ◽  
...  

2016 ◽  
Vol 30 (1) ◽  
pp. 39-47 ◽  
Author(s):  
Hong-Van Tieu ◽  
Vijay Nandi ◽  
Donald R. Hoover ◽  
Debbie Lucy ◽  
Kiwan Stewart ◽  
...  

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S21-S21 ◽  
Author(s):  
Paul Salcuni ◽  
Jenny Smolen ◽  
Sachin Jain ◽  
Julie Myers ◽  
Zoe Edelstein

Abstract Background Concern over equitable access to HIV preexposure prophylaxis (PrEP) informs comprehensive scale-up efforts in New York City (NYC). We examined trends plus patient and practice factors associated with PrEP prescribing by NYC ambulatory care practices. Methods We queried electronic health records (EHR) from Q1 2014 to Q2 2016 using the NYC Health Department’s “Hub.” Data from 602 practices were aggregated quarterly by patient factors, including age (18–29, 30–100); sex (male, female); and race/ethnicity (Asian, Black, Hispanic, White, other, missing). Practice factors included location (Manhattan, other); type (community health center [CHC], hospital, independent); number of infectious disease (ID) specialists; and proportion of patients (ranked by quartile) from high poverty neighborhoods (ZIP codes in which ≥20% of residents live below the federal poverty level). PrEP prescription was defined as tenofovir/emtricitabine prescription without other antiretrovirals or diagnoses of HIV, HIV-related opportunistic infections or hepatitis B. Rates were calculated per 105 patients seen. We used generalized estimating equations clustered by practice to examine trends overall and by sex, as well as associations among males. Factors and time interactions that were significant (P < 0.05) in bivariate analysis were assessed for inclusion in the final model. Results Overall, PrEP prescription rose from 38.9 per 105 in Q1 2014 to 418.5 per 105 in Q2 2016, a 976% increase. Increases were significant for both sexes (P < .0001; Figure 1). In multivariate analysis (Table 1), PrEP prescription was associated with both patient (younger age, white race/ethnicity) and practice factors (Manhattan location, CHCs, and on-site ID specialists). While practices with a greater proportion of patients from high poverty neighborhoods were less likely to prescribe PrEP initially, this association weakened over time (Table 2). Conclusion PrEP prescription increased over 9-fold from 2014 to 2016 among NYC ambulatory care practices, but disparities persisted. While efforts to promote PrEP may have helped attenuate the disparity by neighborhood poverty of the patient population, continued work may be needed to facilitate PrEP access for women, persons of color and for those in care at non-CHCs or practices outside of Manhattan. Disclosures All authors: No reported disclosures.


2011 ◽  
Vol 25 (5) ◽  
pp. 287-293 ◽  
Author(s):  
Lloyd A. Goldsamt ◽  
Michael C. Clatts ◽  
Monica M. Parker ◽  
Vivian Colon ◽  
Renee Hallack ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document